{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:50:31Z","timestamp":1790470231528,"version":"4.1.0"},"reference-count":152,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T00:00:00Z","timestamp":1654387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Acute myeloid leukemia (AML) is a genetically heterogeneous hematological malignancy. Chromosomal and genetic analyses are important for the diagnosis and prognosis of AML. Some patients experience relapse or have refractory disease, despite conventional cytotoxic chemotherapies and allogeneic transplantation, and a variety of new agents and treatment strategies have emerged. After over 20 years during which no new drugs became available for the treatment of AML, the CD33-targeting antibody\u2013drug conjugate gemtuzumab ozogamicin was developed. This is currently used in combination with standard chemotherapy or as a single agent. CPX-351, a liposomal formulation containing daunorubicin and cytarabine, has become one of the standard treatments for secondary AML in the elderly. FMS-like tyrosine kinase 3 (FLT3) inhibitors and isocitrate dehydrogenase 1\/2 (IDH 1\/2) inhibitors are mainly used for AML patients with actionable mutations. In addition to hypomethylating agents and venetoclax, a B-cell lymphoma-2 inhibitor is used in frail patients with newly diagnosed AML. Recently, tumor protein p53 inhibitors, cyclin-dependent kinase inhibitors, and NEDD8 E1-activating enzyme inhibitors have been gaining attention, and a suitable strategy for the use of these drugs is required. Antibody drugs targeting cell-surface markers and immunotherapies, such as antibody\u2013drug conjugates and chimeric antigen receptor T-cell therapy, have also been developed for AML.<\/jats:p>","DOI":"10.3390\/cancers14112806","type":"journal-article","created":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T10:47:11Z","timestamp":1654426031000},"page":"2806","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["New Therapeutic Strategies for Adult Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4456-1286","authenticated-orcid":false,"given":"Hiroto","family":"Ishii","sequence":"first","affiliation":[{"name":"Division of Clinical Oncology & Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 1058461, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology & Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 1058461, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_2","unstructured":"National Comprehensive Cancer Network (2021, December 25). NCCN Clinical Guidelines in Oncology (NCCN Guideline R): Acute Myeloid Leukemia (Version 2.2021). Available online: http:\/\/www.nccn.org."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1056\/NEJM198409273111302","article-title":"High-resolution chromosomes as an independent prognostic indicator in adult acute nonlymphocytic leukemia","volume":"311","author":"Yunis","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","article-title":"Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461)","volume":"100","author":"Byrd","year":"2002","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group\/Eastern Cooperative Oncology Group Study","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network, Ley, T.J., Miller, C., Ding, L., Raphael, B.J., Mungall, A.J., Robertson, A., Hoadley, K., Triche, T.J., and Laird, P.W. (2013). Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med., 368, 2059\u20132074.","DOI":"10.1056\/NEJMoa1301689"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood-2012-06-431122","article-title":"Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: Relevance to post-remission therapy","volume":"121","author":"Pratcorona","year":"2013","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","article-title":"Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation","volume":"124","author":"Schlenk","year":"2014","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.leukres.2018.01.008","article-title":"Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study","volume":"66","author":"Harada","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","article-title":"Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial","volume":"35","author":"Platzbecker","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","article-title":"Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD","volume":"133","author":"Schlenk","year":"2019","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-020-1089-8","article-title":"Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: Feasibility and preliminary efficacy of the Beat AML Master Trial","volume":"26","author":"Burd","year":"2020","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Deshpande, R.P., Sharma, S., and Watabe, K. (2020). The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors. Cancers, 12.","DOI":"10.3390\/cancers12102983"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for Relapsed\/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Dombret","year":"2018","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1200\/JCO.2010.30.5961","article-title":"First-in-man study of CPX-351: A liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia","volume":"29","author":"Feldman","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.leukres.2010.01.015","article-title":"Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine: Daunorubicin formulation, in bone marrow xenografts","volume":"34","author":"Lim","year":"2010","journal-title":"Leuk. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/cncr.28705","article-title":"Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations","volume":"120","author":"Alvarado","year":"2014","journal-title":"Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","article-title":"Acute myeloid leukemia. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm","volume":"100","author":"Schlenk","year":"2002","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2007-08-107946","article-title":"FLT3 D835\/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications","volume":"111","author":"Whitman","year":"2008","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.clml.2018.06.006","article-title":"FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia","volume":"18","author":"Perry","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s12185-019-02720-z","article-title":"Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia","volume":"110","author":"Sakaguchi","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1038\/s41375-021-01179-4","article-title":"Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: The Alliance CALGB 10603\/RATIFY trial","volume":"35","author":"Larson","year":"2021","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: A multicentre, first-in-human, open-label, phase 1-2 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1200\/JCO.2013.48.8783","article-title":"Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status","volume":"31","author":"Cortes","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1470-2045(18)30240-7","article-title":"Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: An open-label, multicentre, single-arm, phase 2 trial","volume":"19","author":"Cortes","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1182\/blood-2018-01-821629","article-title":"Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): A multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2010-01-266742","article-title":"FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo","volume":"117","author":"Sato","year":"2011","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2011-02-334540","article-title":"Rethinking bioactivity of FLT3 inhibitors","volume":"117","author":"Fischer","year":"2011","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2643-3230.BCD-20-0143","article-title":"Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors","volume":"2","author":"Alotaibi","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature11016","article-title":"Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia","volume":"485","author":"Smith","year":"2012","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/leu.2015.165","article-title":"FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors","volume":"29","author":"Smith","year":"2015","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1182\/blood-2011-06-363960","article-title":"Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: Favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation","volume":"119","author":"Man","year":"2012","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1182\/bloodadvances.2019000919","article-title":"Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations","volume":"4","author":"Tarver","year":"2020","journal-title":"Blood Adv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2016-04-711820","article-title":"Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis","volume":"130","author":"Smith","year":"2017","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41467-018-08263-x","article-title":"Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.3324\/haematol.2020.263392","article-title":"A phase I\/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"106","author":"Swaminathan","year":"2021","journal-title":"Haematologica"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3324\/haematol.2019.243410","article-title":"Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: A position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"105","author":"Bazarbachi","year":"2020","journal-title":"Haematologica"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nm0311-291","article-title":"Metabolism unhinged: IDH mutations in cancer","volume":"17","author":"Prensner","year":"2011","journal-title":"Nat. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1084\/jem.20092506","article-title":"Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations","volume":"207","author":"Gross","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/leu.2016.275","article-title":"Isocitrate dehydrogenase mutations in myeloid malignancies","volume":"31","author":"Medeiros","year":"2017","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1158\/1078-0432.CCR-18-0536","article-title":"Targeting the IDH2 Pathway in Acute Myeloid Leukemia","volume":"24","author":"Amaya","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","article-title":"Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib","volume":"133","author":"Stein","year":"2019","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: Characteristics, outcome, and prognostic factors","volume":"113","author":"Montesinos","year":"2009","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","article-title":"Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response","volume":"130","author":"Amatangelo","year":"2017","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","article-title":"Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1\/2 Study","volume":"4","author":"Fathi","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-20-0834","article-title":"Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis","volume":"26","author":"Norsworthy","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3324\/haematol.2012.076729","article-title":"Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia","volume":"98","author":"Shih","year":"2013","journal-title":"Haematologica"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"Schlenk","year":"2012","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/leu.2008.173","article-title":"TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis","volume":"23","author":"Bowen","year":"2009","journal-title":"Leukemia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/cncr.30203","article-title":"TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes","volume":"122","author":"Kadia","year":"2016","journal-title":"Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S2352-3026(18)30182-0","article-title":"Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: A randomised phase 2 trial","volume":"6","author":"Short","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des My\u00e9lodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","article-title":"Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML","volume":"151","author":"Vo","year":"2012","journal-title":"Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","article-title":"BCL-2 inhibition in AML: An unexpected bonus?","volume":"132","author":"Konopleva","year":"2018","journal-title":"Blood"},{"key":"ref_77","first-page":"1758","article-title":"The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics","volume":"5","author":"Kornblau","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1182\/blood-2002-06-1714","article-title":"Amount of spontaneous apoptosis detected by Bax\/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML)","volume":"101","author":"Venditti","year":"2003","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem. Cell"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: A multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"27696","DOI":"10.1038\/srep27696","article-title":"Targeting MCL-1\/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/10428194.2014.910657","article-title":"Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies","volume":"56","author":"Bogenberger","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","article-title":"Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells","volume":"22","author":"Niu","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/leu.2017.243","article-title":"Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1","volume":"32","author":"Teh","year":"2018","journal-title":"Leukemia"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","article-title":"Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells","volume":"91","author":"Tsao","year":"2012","journal-title":"Ann. Hematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","article-title":"5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis","volume":"13","author":"Jin","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs. conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1073\/pnas.090465597","article-title":"A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination","volume":"97","author":"Podust","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.molcel.2009.12.024","article-title":"Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: The NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ","volume":"37","author":"Brownell","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood-2017-09-805895","article-title":"Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML","volume":"131","author":"Swords","year":"2018","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2016.09.007","article-title":"The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2\u03b1 and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia","volume":"50","author":"Leclerc","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12943-019-0979-1","article-title":"Neddylation: A novel modulator of the tumor microenvironment","volume":"18","author":"Zhou","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41420-020-00296-w","article-title":"Pevonedistat (MLN4924): Mechanism of cell death induction and therapeutic potential in colorectal cancer","volume":"6","author":"Ferris","year":"2020","journal-title":"Cell Death Discov."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.13323","article-title":"Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: A phase 1 study","volume":"169","author":"Swords","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e520","DOI":"10.1038\/bcj.2017.1","article-title":"Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes","volume":"7","author":"Swords","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/cdd.2015.74","article-title":"MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors","volume":"22","author":"Knorr","year":"2015","journal-title":"Cell Death Differ."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"6891","DOI":"10.1038\/ncomms7891","article-title":"The NOXA-MCL1-BIM axis defines lifespan on extended mitotic arrest","volume":"6","author":"Haschka","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1182\/blood-2019-131728","article-title":"A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)","volume":"134","author":"Murthy","year":"2019","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/15384101.2016.1138186","article-title":"Overview of CDK9 as a target in cancer research","volume":"15","author":"Morales","year":"2016","journal-title":"Cell Cycle"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"(2018). Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed\/Refractory Acute Myeloid Leukemia (AML). Blood, 132, 30.","DOI":"10.1182\/blood-2018-99-115018"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nrc3090","article-title":"Cyclin D as a therapeutic target in cancer","volume":"11","author":"Musgrove","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0092-8674(95)90385-2","article-title":"The retinoblastoma protein and cell cycle control","volume":"81","author":"Weinberg","year":"1995","journal-title":"Cell"},{"key":"ref_111","first-page":"1633","article-title":"Absence of cyclin D\/cdk complexes in cells lacking functional retinoblastoma protein","volume":"9","author":"Bates","year":"1994","journal-title":"Oncogene"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/26155","article-title":"Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a","volume":"395","author":"Russo","year":"1998","journal-title":"Nature"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ccell.2017.11.006","article-title":"Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib","volume":"32","author":"Gong","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","article-title":"Targeting CDK4 and CDK6: From Discovery to Therapy","volume":"6","author":"Sherr","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1158\/0008-5472.CAN-14-2486","article-title":"CDK4\/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity","volume":"75","author":"Yang","year":"2015","journal-title":"Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","article-title":"Acute myeloid leukemia stem cells and CD33-targeted immunotherapy","volume":"119","author":"Walter","year":"2012","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.intimp.2004.01.002","article-title":"RNA degradation precedes DNA cleavage in autoreactive CD4 T cells suppressed by calicheamicin gamma1","volume":"4","author":"Thomas","year":"2004","journal-title":"Int. Immunopharmacol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/sj.leu.2402677","article-title":"Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)","volume":"16","author":"Larson","year":"2002","journal-title":"Leukemia"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1158\/1078-0432.CCR-18-1897","article-title":"Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia","volume":"25","author":"Tarlock","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: Final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","article-title":"Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation","volume":"102","author":"Wadleigh","year":"2003","journal-title":"Blood"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/10428194.2020.1827247","article-title":"Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin","volume":"62","author":"Ladha","year":"2021","journal-title":"Leuk. Lymph."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.bbmt.2019.12.763","article-title":"Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis","volume":"26","author":"Ho","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: The phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): A multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv."},{"key":"ref_133","first-page":"1794","article-title":"Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL","volume":"139","author":"Siddiqi","year":"2022","journal-title":"Boold"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: Current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V130.Suppl_1.811.811","article-title":"Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"key":"ref_136","first-page":"1261","article-title":"Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies","volume":"86","author":"Carnicer","year":"2001","journal-title":"Haematologica"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2050-7771-2-4","article-title":"CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies","volume":"2","author":"Testa","year":"2014","journal-title":"Biomark Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.2011.047894","article-title":"High levels of CD34+CD38low\/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: A Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study","volume":"96","author":"Vergez","year":"2011","journal-title":"Haematologica"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/leu.2015.288","article-title":"Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia","volume":"30","author":"Wakita","year":"2016","journal-title":"Leukemia"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41375-018-0319-2","article-title":"Single cell analysis of clonal architecture in acute myeloid leukaemia","volume":"33","author":"Potter","year":"2019","journal-title":"Leukemia"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","article-title":"Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges","volume":"10","author":"Short","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2008-05-157065","article-title":"Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients","volume":"113","author":"Sekeres","year":"2009","journal-title":"Blood"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1182\/blood-2012-09-454553","article-title":"Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia","volume":"121","author":"Bertoli","year":"2013","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood.2019004583","article-title":"Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?","volume":"136","author":"Kramer","year":"2020","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/bloodadvances.2020003806","article-title":"Impact of treatment delay in acute myeloid leukemia revisited","volume":"5","author":"Juliusson","year":"2021","journal-title":"Blood Adv."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.bbmt.2014.09.007","article-title":"Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia","volume":"20","author":"Chen","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ajh.24959","article-title":"Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant","volume":"93","author":"Sandmaier","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: An open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"630429","DOI":"10.3389\/fimmu.2021.630429","article-title":"TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis","volume":"12","author":"Gagelmann","year":"2021","journal-title":"Front Immunol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat. Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s12185-009-0480-5","article-title":"Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: The JALSG AML95 study","volume":"91","author":"Ohtake","year":"2010","journal-title":"Int. J. Hematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/11\/2806\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:24:43Z","timestamp":1760138683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/11\/2806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,5]]},"references-count":152,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["cancers14112806"],"URL":"https:\/\/doi.org\/10.3390\/cancers14112806","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,5]]}}}